Literature DB >> 22588354

Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center".

Inci Elif Erbahçeci, Kemal Ornek.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22588354      PMCID: PMC9396814          DOI: 10.1097/IAE.0b013e31825956b8

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   3.975


× No keyword cloud information.
  21 in total

1.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Susan B Bressler; Allison R Edwards; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Kellee M Miller; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2010-04-28       Impact factor: 12.079

Review 2.  Evolving guidelines for intravitreous injections.

Authors:  Lloyd P Aiello; Alexander J Brucker; Stanley Chang; Emmett T Cunningham; Donald J D'Amico; Harry W Flynn; Lisa R Grillone; Steve Hutcherson; Jeffrey M Liebmann; Terrence P O'Brien; Ingrid U Scott; Richard F Spaide; Christopher Ta; Michael T Trese
Journal:  Retina       Date:  2004-10       Impact factor: 4.256

3.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

5.  Pegaptanib for neovascular age-related macular degeneration.

Authors:  Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

6.  Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.

Authors:  David R Fintak; Gaurav K Shah; Kevin J Blinder; Carl D Regillo; John Pollack; Jeffrey S Heier; Hussein Hollands; Sanjay Sharma
Journal:  Retina       Date:  2008 Nov-Dec       Impact factor: 4.256

7.  Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.

Authors:  Teresa Diago; Colin A McCannel; Sophie J Bakri; Jose S Pulido; Albert O Edwards; John M Pach
Journal:  Retina       Date:  2009-05       Impact factor: 4.256

8.  Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Authors:  Jeffrey S Heier; Andrew N Antoszyk; Peter Reed Pavan; Steven R Leff; Philip J Rosenfeld; Thomas A Ciulla; Richard F Dreyer; Ronald C Gentile; Judy P Sy; Gary Hantsbarger; Naveed Shams
Journal:  Ophthalmology       Date:  2006-02-14       Impact factor: 12.079

Review 9.  Endophthalmitis after intravitreal injections.

Authors:  Stephen G Schwartz; Harry W Flynn; Ingrid U Scott
Journal:  Expert Opin Pharmacother       Date:  2009-09       Impact factor: 3.889

10.  Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.

Authors:  John O Mason; Milton F White; Richard M Feist; Martin L Thomley; Michael A Albert; Tarek O Persaud; Jacob J Yunker; Rachel S Vail
Journal:  Retina       Date:  2008-04       Impact factor: 4.256

View more
  2 in total

1.  Causative Microorganisms of Infectious Endophthalmitis: A 5-Year Retrospective Study.

Authors:  Fang Duan; Kaili Wu; Jingyu Liao; Yongxin Zheng; Zhaohui Yuan; Junlian Tan; Xiaofeng Lin
Journal:  J Ophthalmol       Date:  2016-06-19       Impact factor: 1.909

2.  The effect of diluting povidone-iodine on bacterial growth associated with speech.

Authors:  Sivashanth Gnanasekaran; Sophie Rogers; Sanj Wickremasinghe; Sukhpal S Sandhu
Journal:  BMC Ophthalmol       Date:  2019-02-26       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.